Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ENDOSCAPE

Financiado

Cerrado

ENDOSCAPE a clinically applicable non viral gene delivery technology

Gene therapy is one of the most promising treatment options for future advanced therapies in a broad range of diseases. Successful gene delivery requires the recognition of target cells as well as cytosolic and nucleosolic uptake... ver más

30/06/2023

CHARITE UNIVERSIT...

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

CHARITE UNIVERSITAETSMEDIZIN BERLIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-06-30

SC1-BHC-09-2018: Innovation platforms for advanced t...

I+D

Cerrada hace 6 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

CHARITE UNIVERSITAETSMEDIZI...

1.38M€ | Lider

ASISTENCIA ALUMINIO INDUSTRI...

VLAAMS INSTITUUT BIOTECHNOL...

584.09K€ | Participante

MPG

671.88K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2020-117143RB-I00 NUEVAS HERRAMIENTAS QUIMICAS CONCEPTUALES PARA TERAPIA GENIC... 263K€ Cerrado

PID2020-114356RB-I00 VECTORES NO VIRALES PARA TERAPIA GENICA BASADOS EN NANOPARTI... 213K€ Cerrado

inteRNAlizer Efficient, safe, and cost-efficient RNA delivery vehicles fo... 150K€ Cerrado

LentiFactory MAGIC MAnufacturing of Gene delivery tools for Industrial a... 71K€ Cerrado

VLPSIRNA Virus like particles the next step in gene therapy 238K€ Cerrado

UPGRADE Unlocking Precision Gene Therapy 15M€ Cerrado

Duración del proyecto: 55 meses Fecha Inicio: 2018-11-21
Fecha Fin: 2023-06-30

Líder del proyecto

CHARITE UNIVERSITAETSMEDIZIN BERLIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Gene therapy is one of the most promising treatment options for future advanced therapies in a broad range of diseases. Successful gene delivery requires the recognition of target cells as well as cytosolic and nucleosolic uptake of the gene. Currently, non-viral based gene delivery such as transfection reagents are only suitable for in vitro applications, and clinical gene therapeutics delivery is accomplished via viral vectors, which still has major safety concerns as well as complex and costly manufacturing procedures, preventing future implementation for the treatment of diseases with large patients groups. In the last 15 years, a class of secondary plant metabolites has been discovered that selectively mediates endosomal escape and cytoplasmic delivery of macromolecules specifically at low endosomal pH, thereby inducing a 40-fold enhanced gene delivery efficacy in vivo. However, endosomal escape enhancers and gene therapeutic product must be applied as two components, thus complicating therapeutic approval and clinical applicability. The ENDOSCAPE technology platform will develop and collect proof of concept for a non-viral gene delivery technology where endosomal escape enhancers, gene therapeutic product and targeting ligand are all bound to one molecular scaffold. Proof of concept of the ENDOSCAPE technology has a major impact on the therapeutic opportunities for current and future macromolecule drugs for a broad range of diseases and large patient groups. All this induces new biotech-based businesses, new research projects and creates new technology platforms for development of new macromolecule therapeutics for a broad range of disease indications. The non-viral based ENDOSCAPE technology will enhance therapeutic efficacy with lower therapeutic dose thereby reducing costs of healthcare, improving the health of patients worldwide, and strengthening the competitive landscape of the EU in the worldwide quest for such an advanced technology.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores